Prediction: Grail Stock Will Skyrocket to $100 in 1 Year

Grail shares are down >40% from an $116.06 record high to about $69 after its Feb NHS England Galleri trial failed the primary endpoint. Despite the setback, revenue is rising from $93M (2022) to $147M (2025) and is projected to grow ~25% CAGR to $287M by 2028, supported by cash sales ($749–$949) and expansion via Epic’s Aura network. The bullish case hinges on FDA premarket approval in late 2026/early 2027, with a potential upside to ~$100 if approval materially re-rates the stock.

Analysis

The market is treating this less like a one-trial setback and more like a reset in reimbursement probability. That matters because the cash-pay channel can keep unit growth alive, but it does not support a durable premium multiple unless payers eventually underwrite routine screening; the stock’s current weakness is really about the gap between technical adoption and scalable economics.

The second-order winner from a slower regulatory path is the incumbent screening stack: established diagnostics and single-cancer screening names should keep budget share if MCED evidence stays ambiguous. The more important competitive effect is not direct displacement, but that hospital systems and employers will wait for cleaner proof before adding a high-ticket, broad-screen test, which lowers near-term conversion rates for the whole category.

The real catalysts are binary and time-bound: FDA process milestones over the next 3-9 months, then payer policy over 12-18 months. What would falsify the bearish view is an accepted PMA timeline plus evidence of accelerating cash-pay volumes through Epic distribution; what would kill the bullish re-rate is any slip that pushes approval beyond early 2027 or signals CMS will not move in tandem. In other words, this is still a call option on regulation, not a quality compounder yet.

Key Decisions for Investors

• Do not chase a straight common-stock rebound in GRAL here; use any squeeze toward the mid-$70s to reduce exposure unless FDA process milestones improve. Risk/reward is still dominated by a binary reimbursement outcome over the next 3-12 months.
• Pair trade: long EXAS / short GRAL over the next 1-3 months if you want MCED-category exposure without paying for the highest regulatory optionality. This works if payers keep favoring established screening economics over broad multi-cancer screening promises.
• For bullish optionality, prefer a defined-risk structure such as GRAL Jan-2027 $80/$120 call spread rather than outright shares. You keep upside to a PMA-led rerating while capping downside if the approval clock slips.
• Set a hard alert on FDA PMA acceptance and any CMS coverage language; those are the true re-rating events. If there is no formal progress by 2H26, the thesis shifts from 'temporary setback' to 'structural commercialization delay.'